
Ras
Ras proteins are small GTPases that act as molecular switches in the MAPK signaling pathway, controlling cell growth, differentiation, and survival. Activated Ras initiates a signaling cascade that includes Raf, MEK, and ERK, leading to various cellular responses. Mutations in Ras genes are common in cancers, making Ras an important focus of cancer research. At CymitQuimica, we offer a range of Ras modulators to support your research in cancer biology, signal transduction, and therapeutic development.
Found 155 products of "Ras"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Formula:C27H24F3N7O2Color and Shape:SolidMolecular weight:535.52KRAS inhibitor-32
CAS:<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Formula:C29H35FN10OS2Color and Shape:SolidMolecular weight:622.78BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Formula:C25H23N5O2S2Purity:99.58% - 99.58%Color and Shape:SolidMolecular weight:489.61pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Formula:C22H26N8OSColor and Shape:SolidMolecular weight:450.56KRAS inhibitor-37
CAS:<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Formula:C32H33ClFN7O3Color and Shape:SolidMolecular weight:618.10KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Formula:C32H37N7O3Purity:98%Color and Shape:SolidMolecular weight:567.68Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Formula:C27H41NO8Color and Shape:SolidMolecular weight:507.616ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Formula:C24H18N2O7S2Color and Shape:SolidMolecular weight:510.539KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Formula:C33H30F3N5O4Color and Shape:SolidMolecular weight:617.62XMU-MP-9
CAS:<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Formula:C19H13ClFN3OSColor and Shape:SolidMolecular weight:385.84AM-001
CAS:<p>AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.</p>Formula:C24H16FN3OS2Color and Shape:SolidMolecular weight:445.53KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Formula:C38H32F4N6O3SColor and Shape:SolidMolecular weight:728.76KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formula:C30H37FN10OSColor and Shape:SolidMolecular weight:604.745Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Formula:C36H39ClFN7O4Color and Shape:SolidMolecular weight:688.191KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Formula:C35H32Cl2FN5OColor and Shape:SolidMolecular weight:628.57
